-
Publication Venue For
-
A Beginner's Guide to Understanding Curative Therapies..
22:619-620.
2019
-
Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations..
22:684-692.
2019
-
Novel Approaches to Value Assessment Beyond the Cost-Effectiveness Framework..
22:S18-S23.
2019
-
PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains..
22:537-544.
2019
-
The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments..
22:157-160.
2019
-
Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data..
22:77-84.
2019
-
Psychometric Evaluation of the Patient's Knee Implant Performance Questionnaire..
21:1305-1312.
2018
-
Advancing Value Assessment in the United States: A Multistakeholder Perspective..
20:299-307.
2017
-
Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine..
20:32-39.
2017
-
Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants..
19:996-1001.
2016
-
International Experiences in Quantitative Benefit-Risk Analysis to Support Regulatory Decisions..
19:727-729.
2016
-
Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective..
19:741-745.
2016
-
A PROMIS Measure of Neuropathic Pain Quality..
19:623-630.
2016
-
Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force..
19:300-315.
2016
-
Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness..
19:185-191.
2016
-
Responsiveness to Change in PROMIS(®) Measures among Children with Asthma: A Report from the PROMIS(®) Pediatric Asthma Study..
19:192-201.
2016
-
Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer's Disease..
19:66-74.
2016
-
The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?.
19:88-98.
2016
-
A Vision "Bolt-On" Item Could Increase the Discriminatory Power of the EQ-5D Index Score..
18:1037-1042.
2015
-
The Value Adults Place on Child Health and Functional Status..
18:449-456.
2015
-
Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report..
18:161-172.
2015
-
Physicians' preferences for bone metastases drug therapy in the United States..
18:78-83.
2015
-
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes..
17:854-862.
2014
-
US valuation of health outcomes measured using the PROMIS-29..
17:846-853.
2014
-
Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening..
17:838-845.
2014
-
Effect of Oral Nutritional Supplements On Hospital Outcomes in Patients Aged 65+ With Congestive Heart Failure..
17:A503.
2014
-
Patients' Preferences for Bone Metastases Treatments in Turkey..
17:A648.
2014
-
Physicians' Preferences for Bone Metastases Treatments in Turkey..
17:A570.
2014
-
The Value of Diagnostic Tests for Alzheimer's Disease: Discrete-Choice Experiment and Contingent-Valuation..
17:A402.
2014
-
Understanding Medication Adherence Using Stated-Preference Data..
17:A492-A493.
2014
-
A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer..
17:545-554.
2014
-
Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment..
16:385-393.
2013
-
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force..
16:3-13.
2013
-
A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs..
15:1014-1021.
2012
-
PRM145 A Maximum Likelihood Simulation Technique for Estimating Adverse Event Rates From Published Trials..
15:A487.
2012
-
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response..
15:876-886.
2012
-
Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States..
15:632-638.
2012
-
Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial..
15:277-283.
2012
-
Assuring the patient centeredness of patient-reported outcomes: content validity in medical product development and comparative effectiveness research..
14:965-966.
2011
-
Development, reliability, and validity of a new Preference and Satisfaction Questionnaire..
14:1109-1116.
2011
-
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia..
14:1055-1056.
2011
-
Evaluating patient-reported outcome measurement comparability between paper and alternate versions, using the lung function questionnaire as an example..
14:712-720.
2011
-
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force..
14:403-413.
2011
-
Utility scores and treatment preferences for clinical early-stage cervical cancer..
14:582-586.
2011
-
The CHD challenge: comparing four cost-effectiveness models..
14:53-60.
2011
-
Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes..
13:418-423.
2010
-
Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome..
13:411-417.
2010
-
Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States..
12:666-673.
2009
-
Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report..
12:409-418.
2009
-
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy..
12:217-225.
2009
-
Editorial: Moving the QALY forward or just stuck in traffic?.
12 Suppl 1:S38-S39.
2009
-
Using conjoint analysis to estimate healthy-year equivalents for acute conditions: an application to vasomotor symptoms..
12:146-152.
2009
-
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation..
11:1022-1032.
2008
-
Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza..
11:160-171.
2008
-
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy..
11:172-179.
2008
-
Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis..
10:489-497.
2007
-
What is sufficient evidence for the reliability and validity of patient-reported outcome measures?
2007